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Background
Clostridium difficile is currently considered a significant
cause of nosocomial infection and is associated with
increasing morbidity and mortality. The probability of
colonization of hospitalized patients increases with the
length of their hospital stay and depends on the local
epidemiologic situation.
The study aimed to evaluate the epidemiological, clini-
cal and treatment features of Clostridium difficile colitis
(CDC), and the relapse associated risk factors in the
Infectious Diseases Clinic and Gastroenterology Clinic.
Methods
Prospective study of cases admitted to our clinic with
CDC in the last year. The following parameters were
analyzed: age, sex, comorbidities, recent hospitalizations,
recent surgery, use of antibiotics, use of proton pump
inhibitors (PPIs), clinical form of the disease, methods
of diagnosis and therapeutic response.
Results
In the two Clinics, 42 patients were diagnosed and treated
in the last year (14 times more than during 2011-2012).
More than half of the cases had severe clinical forms
(pancolitis). We recorded no case of toxic megacolon. All
patients reported use of antibiotics, most frequently fluor-
oquinolones and cephalosporins (48% and 34%). 68% of
patients had history of prolonged hospitalizations in
orthopedics, surgery, oncology or hematology clinics and
82% of patients had comorbidities (leukemia, cancer, liver
cirrhosis). The toxin (A and B) test was positive in only
half of cases, in all cases the diagnosis was confirmed by
sigmoidoscopy. Metronidazole, vancomycin and rifaximin
were administered in 68% of cases, intravenous metroni-
dazole, ertapenem and rifaximin in 10% of cases, metroni-
dazole orally and rifaximin in 10% of cases and only 12%
of cases responded favorably to metronidazole alone. We
recorded relapses in 9 patients (21.4%). Relapse associated
risk factors were: malignant diseases, inflammatory bowel
disease, IPP treatment, colonic resection, immunosup-
pressive therapy and absence of rifaximin regimen.
Conclusion
Interdisciplinary collaboration is vital for limiting the
development of this very serious, often fatal disease.
Rational use of antibiotic therapy is essential, particularly
in an environment contaminated by spores of Clostridium
difficile. We need to examine the possibilities of using
vaccines to combat infection due to Clostridium difficile in
real life and clinical trials.
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